Biomarker Commons

Kantar Health, a leading global healthcare consulting firm, today announced the availability of CancerMPact® Biomarker Analysis, a global offer that examines biomarker segmentation in the current and evolving oncology landscape. The analysis is based on a thorough review of literature and recently published data covering the following biomarkers:

• BRAF (melanoma)
• EGFR (non-small lung cancer)
• EML4-ALK (non-small cell lung cancer)
• KRAS (colorectal cancer)
• TNBC (breast cancer)

As part of its mission to capture a share of the fast-growing, $232 billion personalized medicine market, Rainbow Coral Corp. (OTCBB: RBCC) is making plans to empower patients to demand better care through a potent combination of innovation and education.

Critical Diagnostics announced recently that the Journal of Hypertension published a study titled, “Soluble ST2 Predicts Elevated SBP in the Community.” The results showed that a cohort of ostensibly healthy individuals, except for the presence of high levels of the biomarker ST2 in their blood, were almost twice as likely to develop hypertension in the future than those with low ST2 levels.

Ignyta, Inc. recently announced that it has acquired Actagene Oncology, Inc., effective May 20, 2013. Actagene was a San Diego based privately held biotechnology company founded in February 2013 that was developing personalized medicines for high unmet need cancer indications, based on cancer genome mining and sequencing.

med fusion and Theranostics Health will introduce the first of the TheraLink™Assays for use in patients with malignant diseases at the American Society of Clinical Oncology (ASCO) Annual '13 Meeting, held in Chicago, IL from May 31, 2013 through June 4, 2013. The TheraLink™ HER Family Assay for primary, recurrent and metastatic breast cancers provides a molecular analysis of each patient's unique cancer, based upon the functional activity of signal transduction pathways known to modulate cancerous growth.